Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986209 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A:SAD | EXPERIMENTAL | Single Ascending Dose |
| Part B: MAD | EXPERIMENTAL | Multiple Ascending Dose |
| Part C: DDI | EXPERIMENTAL | Drug-Drug Interaction |
| Part A (SAD) Placebo | EXPERIMENTAL | - |
| Part B (MAD) Placebo | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986209 | DRUG | Specified Dose on Specified Days |
| BMS-986209 Placebo | OTHER | Specified Dose on Specified Days |
| Itraconazole | DRUG | Specified Dose on Specified Days |
| Diltiazem | DRUG | Specified Dose on Specified Days |
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com. Inclusion Criteria: * Healthy male and female participants (not of childbearing potential) as determined by no deviation considered significant by the investigator from normal in...
BMS-986209 is an investigational small molecule drug developed by Bristol-Myers Squibb Company. It has been studied in a Phase 1 clinical trial in healthy adult participants. The specific disease indications being explored for BMS-986209 have not been publicly disclosed.
BMS-986209 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The company sponsored the Phase 1 clinical trial evaluating the drug in healthy participants.
BMS-986209 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug is investigational and has not been approved by the FDA for any indication.
BMS-986209 has been evaluated in one clinical trial, NCT04154800, titled A Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of Single and Multiple Doses of BMS-986209 in Healthy Participants. The Phase 1 trial was completed and enrolled 114 healthy adult participants in the United States.
The Phase 1 trial NCT04154800 was a randomized, double-blind, controlled study of single and multiple doses of BMS-986209 in 114 healthy adult participants of all sexes, aged 18 years and older. It was conducted in the United States and has been completed.